+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer

, : Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer. Oncology 11(4 Suppl 3): 11-14

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC) to receive one of two cisplatin (Platinol)-based chemotherapy regimens: Paclitaxel (Taxol) 175 mg/m2 given by 3-hour infusion followed by cisplatin 80 mg/m2 on day 1; Or cisplatin 80 mg/m2 on day 1, followed by teniposide (Vumon) 100 mg/m2 given on days 1, 3, and 5. Cycles were repeated every 3 weeks. Preliminary analysis of the results of this phase III trial shows that hematologic toxicity was decidedly more severe in the group treated with cisplatin/teniposide than in those given paclitaxel/cisplatin. Of 264 patients evaluable so far, responses have been observed in 47% of those given paclitaxel and in 29% of those treated with teniposide. However, extramural radiologic response evaluation is still under way, so these figures are expected to change somewhat. It appears clear that the paclitaxel-based therapy affords a benefit in terms of response and toxicity, but survival results are premature and any definite conclusions await final analysis.


PMID: 9144684

Other references

E.Z.iny M.; Girgis A.; Iskander K., 1989: Tissue response to tricalcium phosphate and durapatite implants. Journal of Dental Research 68(SPEC ISSUE JUNE): 876

Gazina, E.V.; Fielding, J.E.; Lin, B.; Anderson, D.A., 2000: Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses. To clarify the role of core protein phosphorylation in pregenomic-RNA encapsidation of human and duck hepatitis B viruses (HBV and DHBV, respectively), we have examined the phosphorylation states of different forms of intracellular HBV core protei...

Rozenberg, V.D., 1987: Characteristics of Holt-Oram syndrome. Terapevticheskii Arkhiv 59(4): 135-136

Rampersad, A.; Mukundan, D., 2009: Fever. A comprehensive review of the current advances in the field of fever in children is presented. Clinical and diagnostic predictors of serious disease in a child with fever are still being explored for early diagnosis so that therapy could be approp...

Mallick, N.P., 1989: Dialysis in the management of the renal failure of myeloma. Quarterly Journal of Medicine 73(270): 871-872

Sakimoto, M., 1983: Phosphoric acid precolumn for g. Nihon Chikusan Gakkai ho = Japanese journal of zootechnical science 54(2): 115-116

Anonymous, 2012: IU and Regenstrief to collaborate with 19 Indiana nursing facilities to improve care. A multi-million-dollar award from the Centers for Medicare & Medicaid Services, or CMS, will enable Indiana University and Regenstrief Institute clinician-researchers to work with 19 central Indiana nursing facilities to improve the quality of car...

Okuda, Y.; Hashimoto, A.; Yamaguchi, T.; Fukushi, H.; Mori, S.; Tani, M.; Hirai, K.; Carmichael, L., 1993: Repeated canine herpesvirus (CHV) reactivation in dogs by an immunosuppressive drug. To examine the possibility of repeated reactivation of canine herpesvirus (CHV), 2 serial treatments with the corticosteroid drug prednisolone (PD) were given at different periods following oral-nasal infection of pups and adult dogs. CHV was not...

DeJesus, R.S.; Radecki Breitkopf, C.; Rutten, L.J.; Jacobson, D.J.; Wilson, P.M.; S.S.uver, J., 2016: Incidence Rate of Prediabetes Progression to Diabetes: Modeling an Optimum Target Group for Intervention. NlmCategory="UNASSIGNED">Thirty-seven percent of US adults have prediabetes. Various interventions can delay diabetes progression; however, the optimum target group for risk reduction is uncertain. This study estimated rate of progres...

Boissonnas, R.A., 1968: Synthetic polypeptides with enhanced biological activities. Advan Exp Med Biol 2: 17